1. Safety and Efficacy of Novel ADVD Regimen in an Adult Patient With Early-Stage Hodgkin Lymphoma and Hypoplastic Left Heart Syndrome: Case Report.
- Author
-
Lee, Crystal, Heers, Hayley, Lundquist-Crabbe, Tamara, Stanford, Amanda, and Klueppelberg, Horst
- Abstract
BACKGROUND: Classical Hodgkin lymphoma (cHL) is a curable hematologic malignancy that is more prevalent in young adults than in other age-groups. Thus, maintaining treatment intensity while minimizing acute and long-term adverse events (AEs) are priorities during treatment. Currently, the recommended chemotherapy regimens for newly diagnosed cHL include ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine) and AAVD (doxorubicin, brentuximab vedotin, vinblastine, and dacarbazine). However, the use of these regimens is limited by patient-specific factors, such as baseline cardiopulmonary function. In other treatment settings, liposomal doxorubicin has been an alternative treatment to conventional doxorubicin given the reduced cardiotoxicity with this formulation. DISCUSSION: In this novel case report, we describe the safety and efficacy of ADVD (brentuximab vedotin, pegylated liposomal doxorubicin [PLD], vinblastine, and dacarbazine), a modified AAVD regimen that replaces conventional doxorubicin with PLD, in a patient with newly diagnosed cHL and hypoplastic left heart syndrome. Our patient achieved a complete response after receiving 4 cycles of ADVD followed by consolidative radiation, and no significant AEs were noted. Of note, there were no changes in cardiac function with ongoing surveillance. CONCLUSION: ADVD was well-tolerated and efficacious in our patient with newly diagnosed cHL and congenital heart disease. To our knowledge, this is the first report of the use of PLD in place of conventional doxorubicin in this setting. Further studies are needed regarding the optimal dosing of PLD in patients with newly diagnosed cHL. [ABSTRACT FROM AUTHOR]
- Published
- 2024